Stock Analiz

Pelthos Therapeutics Inc. PTHS

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2024 · data as of November 13, 2026

$7.44Market cap $29M
Open the interactive analysis →

Pelthos Therapeutics Inc. (PTHS) is a healthcare company listed in the US with a market value of about $29M. In the twelve months to September 30, 2026 it had revenue of $51M and net income of -$78M, a net margin of -152.2%.

Its overall Stock Analiz score is 0.0 out of 5 (weak). The strongest part is value (0/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -38%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 33% below the current price.

About Pelthos Therapeutics

Pelthos Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2024. It was profitable in 0 of the last 4 years in our data. Its share count rose by 4220% over three years (dilution for shareholders). It spends 7% of revenue on research and development.

Score: 0.0 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health0/5
Shareholder returns0/5

Checks passed

  • —

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.6
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-111.3%
Shareholder yield0.0%
Intrinsic value vs. price−33%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-257.9%
ROIC (5-yr avg.)-37.6%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 4 years

Fiscal yearTTM2025202420232022
Revenue$51M$17M$0——
Net income-$78M-$43M-$8M-$7M-$2M
Free cash flow-$33M-$23M-$6M——
EPS (diluted)$-23.90$-11.52$-7.13$-28.90$28.25
Net margin-152.2%-257.9%———
ROIC—-37.6%———

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 7 analysts is $41.43, 457% above the current price; targets range from $21.00 to $60.00; the consensus rating is “Strong buy”; expected EPS is $-17.60 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Pelthos Therapeutics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 33% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Pelthos Therapeutics pay a dividend?

Not currently.

Is Pelthos Therapeutics a good stock to buy?

We do not give buy or sell advice. Pelthos Therapeutics scores 0.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.